Results 101 to 110 of about 34,514 (296)

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments.
Nagomi Kurebayashi, Masami Kodama, Hana Inoue, Masato Konishi, Masami Sugihara, Takashi Murayama, Ryosuke Ishida, Koichiro Ishii, Shuichi Mori, Yukari Endo, Xi Zeng, Yukiko U. Inoue, Takayoshi Inoue, Satoru Noguchi, Hajime Nishio, Eri Nakashima, Norio Suzuki, Noriko Nakaya, Ryushi Sato, Yuya Otori, Ayuna Tsutsumi, Mirei Takahashi, Takayuki Oka, Haruo Ogawa, Kayoko Kanamitsu, Hiroyuki Kusuhara, Utako Yokoyama, Junko Kurokawa, Hiroyuki Kagechika, Takashi Sakurai   +29 more
wiley   +1 more source

Oral factor Xa inhibitors for stroke prevention in patients with device-detected atrial fibrillation – Recent evidence from the NOAH-AFNET 6 and ARTESiA trials

Cardiologia Hungarica
Device-detected atrial fibrillation (AF), also known as atrial high rate episodes, is a frequent finding in patients with a cardiac implantable electronic device such as a pacemaker, or an implantable cardioverter-defibrillator or loop recorder.
Alexander P. Benz, William F. McIntyre
doaj   +1 more source

Pacemakers and implantable cardioverter defibrillators [PDF]

Anaesthesia, 2006
Summary An increasing number of patients are now treated cardiac pacemakers and implantable cardioverter defibrillators and the technology of these is constantly changing. It is vital to have a good understanding of how they function and what the real risks are.
openaire   +2 more sources

Sleep disturbance in patients with an implantable cardioverter defibrillator: Prevalence, predictors and impact on health status [PDF]

, 2017
Background:  Sleep disturbances are highly prevalent in patients with cardiac diseases and associated with poor health outcomes. However, little is known about sleep disturbance in patients with an implantable cardioverter defibrillator.
SS Pedersen, L Mudde, Widdershoven, J., Schoormans, D., M Habibović, Mudde, L., J Widdershoven, Pedersen, S. S.; id_orcid, Pedersen, S S, D Schoormans, J Denollet, Habibović, M., Widdershoven, J.W.M.G., Mudde, L, Denollet, J., Habibović, M   +15 more
core   +1 more source

Optimization of novel compounds using computer‐aided drug design for treatment of cardiac arrhythmia

British Journal of Pharmacology, EarlyView.
Background and Purpose Loss‐of‐function mutations of the voltage‐gated Kv7.1 (KCNQ/KCNE1) channels lead to cardiac arrhythmia such as long QT syndrome, characterized by a prolonged QT interval . One strategy to correct the prolonged QT interval is to design molecules that activate KCNQ1/KCNE1 channels and restore the QT interval.
Jessica Jowais, Laura M. Castro‐Gonzalez, Alessia Golluscio, D. Peter Tieleman, H. Peter Larsson   +4 more
wiley   +1 more source

Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance

, 2015
Background: As implantable cardioverter-defibrillator technology evolves, clinicians and patients need reliable performance data on current transvenous implantable cardioverter-defibrillator systems.
Hauser, Robert G, Kramer, Daniel, Hatfield, Laura, Ellis, Christopher R, Retel, Linda Kallinen, McGriff, Deepa, Samuel, Michelle, Gura, Melanie T   +7 more
core   +1 more source

Long-term Outcome of Implantable Cardioverter/Defibrillator Lead Failure.

, 2020
To access publisher's full text version of this article click on the hyperlink belowThis study compares outcomes of a recalled implantable cardioverter/defibrillator lead with a control lead in individuals in ...
Jonsdottir, Gudlaug M, Arnar, David O, Oddsson, Hjortur, Lund, Sigrun H, Davidsson, Gustav Arnar   +4 more
core   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

The Lived Experience of Spouses of People with Implantable Cardioverter Defibrillator: A Phenomenological Hermeneutics Study [PDF]

, 2017
Introduction: Implantable cardioverter defibrillator (ICD) is a vital device for the treatment and control of heart dysrhythmia. This study aimed to determine the lived experience of spouses of people with implantable cardioverter defibrillator. Method:
Abbasi, Mohammad, Negarandeh, Reza, Mollazadeh, Reza, Abbasinia, Mohammad   +3 more
core  

Living with uncertainty : main concern for recipients of implantable cardioverter defibrillator - a qualitative study

, 2010
Background:the implantable cardioverter defibrillator is a sophisticated and multifunctional device to treat life-threatening arrhythmias. With increasing numbers of recipients implanted due to rapid technical development of devices and enlarged ...
Johansson, Ingela,, Flemme, Inger,, Strömberg, Anna,, Hallberg, Ulrika,   +3 more
core   +1 more source